Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Decheng Capital is a venture capital firm founded in 2012, with offices located in Silicon Valley, Shanghai, and New York. The firm specializes in providing capital and strategic support to early-stage life science companies that possess innovative technologies, as well as growth-stage healthcare companies that have established market presence. Currently, Decheng Capital manages over $2 billion in assets under management (AUM) and collaborates with a network of prominent limited partners to drive innovation in the life sciences sector.
Since its inception, Decheng Capital has focused on cross-border investments, particularly between the United States and China. The firm has established a reputation for identifying and supporting transformative technologies that can significantly improve patient outcomes and healthcare delivery. Notable milestones include multiple successful IPOs and acquisitions, validating its investment thesis and approach.
Decheng Capital primarily invests in early-stage life science companies and growth-stage healthcare companies. The firm targets sectors such as biopharma, diagnostics and tools, medical devices, and healthcare services. Investment stages range from pre-seed to growth equity, allowing the firm to engage with companies at various points in their development.
The firm emphasizes revolutionary technologies that can enhance healthcare delivery and patient outcomes. Decheng Capital's investment strategy is characterized by a strong preference for cross-border opportunities, leveraging the rapid growth of China's healthcare market alongside US innovation. The firm seeks to partner with founders who demonstrate a clear vision and the capability to execute their business plans effectively.
Decheng Capital's portfolio includes several notable companies that exemplify its focus on life sciences and healthcare:
Additionally, the firm has been involved with companies like Aardvark Therapeutics, which recently secured $85 million in Series C financing, and has established relationships with major pharmaceutical companies, enhancing its portfolio's potential for successful exits.
Min Cui, Ph.D.: Founder and Managing Director. Min has extensive experience in venture capital and life sciences, having previously worked at leading firms in the industry.
Victor Tong, Jr.: Managing Director. Victor specializes in healthcare investments and has a strong background in both operational and investment roles.
Peter Colabuono: Managing Director. Peter brings expertise in biopharma and has led several successful investments in the sector.
Dayton Misfeldt: Partner. Dayton has a background in healthcare technology and focuses on identifying innovative startups.
Tony Tong, Ph.D.: Partner. Tony has a strong academic background and experience in biotech investments.
Y. Katherine Xu, Ph.D.: Partner. Katherine specializes in medical devices and has a track record of successful investments in the field.
Qiang Xu, Ph.D.: Partner. Qiang focuses on diagnostics and has extensive experience in the life sciences sector.
Wei Xu: Partner. Wei has a background in operational roles within healthcare companies.
Aaron Li, MBA: Vice President. Aaron supports investment analysis and portfolio management.
Yang Lu, MBA: Vice President. Yang focuses on market research and investment strategy.
Michael Notaras, Ph.D.: Vice President. Michael specializes in biotech and healthcare investments.
Shengyang Jin, Ph.D.: Associate. Shengyang supports deal sourcing and due diligence.
Nick Pliam, M.D., Ph.D.: Venture Partner. Nick brings clinical expertise and insights into healthcare investments.
To pitch Decheng Capital, founders should use the preferred channel available on their website at decheng.com. The pitch deck should include a comprehensive overview of the business model, market analysis, competitive landscape, and details about the founding team. Founders can expect a response within a few weeks, and warm introductions are preferred to facilitate the process.
In March 2023, Decheng Capital announced its involvement in Aardvark Therapeutics' $85 million Series C financing, highlighting its active role in supporting innovative healthcare companies.
In February 2023, the firm facilitated a significant gene editing deal worth $100 million between Mammoth Biosciences and Regeneron, showcasing its strong connections within the pharmaceutical industry.
Decheng Capital is currently targeting $700 million for its fifth fund, focusing on life sciences investments, which reflects strong demand from limited partners despite a challenging fundraising environment.
What are Decheng Capital's investment criteria?
Decheng Capital invests in early-stage life science companies and growth-stage healthcare companies, focusing on sectors such as biopharma, diagnostics, medical devices, and healthcare services. The firm looks for revolutionary technologies that can improve patient outcomes and healthcare delivery.
How can founders apply or pitch to Decheng Capital?
Founders can pitch to Decheng Capital through their website at decheng.com. It is advisable to include a detailed business plan, market analysis, and information about the founding team in the pitch deck.
What makes Decheng Capital different from other venture firms?
Decheng Capital's unique focus on cross-border investments between the US and China allows it to leverage significant growth opportunities in both markets. The firm has established strong relationships with major pharmaceutical acquirers, enhancing its portfolio companies' exit potential.
What is the geographic scope of Decheng Capital's investments?
The firm invests globally, with a strong emphasis on the United States and China. This dual focus enables Decheng Capital to capitalize on the rapid growth of the healthcare sector in both regions.
What is the typical check size for investments?
Decheng Capital invests across various stages, with check sizes typically ranging from pre-seed to growth equity, allowing flexibility in funding amounts based on the company's needs and stage of development.
What kind of post-investment involvement does Decheng Capital have?
Decheng Capital provides strategic support to its portfolio companies, leveraging its extensive network of industry contacts and insights into market trends. The firm actively engages with founders to help navigate challenges and capitalize on opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.